CMS Rolls Out Value-Based Gene Therapy Model for Sickle Cell Disease

CMS Rolls Out Value-Based Gene Therapy Model for Sickle Cell Disease

(MedPage Today) -- The Centers for Medicare & Medicaid Services (CMS) announced Tuesday that 33 states, as well as the District of Columbia and Puerto Rico, have agreed to participate in the Cell and Gene Therapy (CGT) Access Model, which is...

33 states pick up CMS program to pay for sickle cell gene therapies

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government to negotiate pay-for-performance deals with the manufacturers of products like Casgevy and Lyfgenia.

CMS Launches Value-Based Gene Therapy Program for Sickle Cell Disease

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., and Puerto Rico, have signed on, collectively covering about 84% of Medicaid enrollees with sickle cell disease.

CMS Launches Cell and Gene Therapy (CGT) Access Model for Medicaid Sickle Cell Patients

What You Should Know:  – The Centers for Medicare & Medicaid Services (CMS) launches its Cell and Gene Therapy (CGT) Access Model, a new approach to delivering cutting-edge treatments for people on Medicaid living with sickle cell disease.  – A total of 33 states, plus the District of Columbia and Puerto Rico, will participate in this model, collectively representing approximately 84% of Medicaid beneficiaries with the condition, significantly e…